Octreoscan (Indium In-111 Pentetreotide)

Octreoscan is a radiolabeled somatostatin analog used in diagnostic imaging of neuroendocrine tumor pathways. It assists clinicians in locating and staging disease.

• Gastroenteropancreatic neuroendocrine tumors: enables whole‑body scintigraphic detection of somatostatin‑receptor positive lesions.
• Bronchial and thymic carcinoids: highlights receptor‑rich tumors for surgical planning.
• Metastatic disease assessment: determines extent of spread to guide therapeutic decisions.

• Indium In-111 pentetreotide binds with high affinity to somatostatin receptor subtypes 2 and 5 on the surface of neuroendocrine cells. After intravenous administration, the radiolabelled complex is internalized, and the emitted gamma photons are captured by a gamma camera, producing images that reflect receptor density and tumor location.

Adverse reactions are generally mild and related to the radiopharmaceutical or injection process.

Common Side Effects

• Nausea: transient feeling of queasiness after injection.
• Flushing: brief warmth or redness of the face and neck.
• Mild headache: short‑lasting discomfort.
• Injection site pain: soreness at the venipuncture site.
• Transient hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): difficulty breathing, hives, or swelling.
• Significant hypotension: prolonged low blood pressure requiring intervention.
• Radiation‑induced marrow suppression: decreased blood counts.
• Renal toxicity: impaired kidney function in susceptible patients.

Octreoscan should be administered by qualified personnel in a setting equipped for nuclear medicine procedures.

• Pregnancy: avoid use unless clearly needed, as radiation may affect fetal development.
• Breastfeeding: discontinue breastfeeding for an appropriate period after administration.
• Renal function: assess kidney function before use; adjust protocol if impairment is present.
• Allergy history: verify no prior hypersensitivity to somatostatin analogs or indium‑111 compounds.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreoscan may interact with agents that affect somatostatin receptors or alter radiation distribution.

Major Interactions (Avoid)

• Long‑acting somatostatin analog therapy (e.g., octreotide LAR): may compete for receptor binding and reduce imaging sensitivity.

Moderate Interactions (Monitor Closely)

• Diuretics: can modify renal clearance of the radiotracer.
• ACE inhibitors: may influence blood pressure response during injection.
• Antihistamines: may mask early signs of an allergic reaction.
• Radioprotective agents: could alter image quality if administered concurrently.